during the last week ofcombined therapy. In four patients the rise in plasma phenytoin was associated with the development of signs of phenytoin toxicity. Discon with no history of non-compliance, gave their informed consent to take part in the study, which was approved by a local ethics committee. After a two week observation period, each patient was started on viloxazine (Vicilan, ICIPharma, Milan), 50 mg three times a day orally for three days, increased thereafter according to toleration to 100 mg three times a day for a total treatment period of 'three weeks. The plasma concentration of phenytoin, the dosage of which was maintained unchanged throughout the study, was measured by enzyme immunoassay (EMIT) at weekly intervals before, during, and after viloxazine treatment.
Comparison of phenytoin concentration values at different times during the study was made by analysis of variance. All values reported in the text are given as means (SD).
Results
All patients completed the study. Five subjects (patients 1, 3, 4, 7, 9) reported transient gastric discomfort or general obtundity, or both, during the first week of viloxazine therapy, and their initial daily dose (150 mg) remained unaltered for the duration of the study. In all other cases viloxazine dosage was increased on day four to 300 mg daily without untoward effects, except for patient 5 who developed symptoms of gastric irritation and required a reduction in viloxazine dosage to 200 mg after two further days. Mean plasma phenytoin levels at different times during the study period are shown in the table. After intake of viloxazine, plasma phenytoin levels rose from a mean value of 19 ig/ml at baseline to a mean value of 26 jg/ml after two weeks on combined therapy. Although a rise in plasma phenytoin was observed in all patients, the magnitude of the percentage increase (37% on average) showed considerable interindividual variability, ranging in different subjects from 7% to 94%. Twelve to 16 days after initiation of viloxazine treatment, four patients presented with clinical symptoms (ataxia and nystagmus) suggestive of phenytoin intoxication. The plasma concentrations ofphenytoin at that time in these patients were 32-3, 39-6, 36-2, and 41-0 ug/ml, which are well within the toxic range (table). In each of these cases, viloxazine was discontinued prematurely, resulting in a rapid decrease in plasma phenytoin and disappearance of the clinical symptoms. A decrease of plasma phenytoin levels towards baseline Elevation ofplasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction Table Individual plasma phenytoin (PHT) concentrations (pg/mli determined at end of each of seven study weeks before (weeks 1 and 2), during (weeks 3, 4, 5) and after (weeks 6 and 7) administration of viloxazine ( VLX). Plasma PHT concentrations during VLX treatment were significantly higher than those observed before VLX (p < 0 001). The magnitude of elevation in plasma phenytoin levels showed a wide interpatient variability (from a minimum of 7% to a maximum of 94%) and was not apparently related to viloxazine dosage. This variability could berelated to interindividual differences in viloxazine pharmacokinetics" or to the dose-dependent nature of phenytoin metabolism, which results in disproportionate changes in plasma drug levels whenever the metabolising enzyme system approaches saturation."4
The occurrence of an interaction with phenytoin and carbamazepine does not preclude the use of viloxazine in epileptic patients who develop depression requiring pharmacological treatment. Viloxazine has been shown to exert antiepileptic activity in experimental models,35 though a pro-convulsant effect has been observed at higher doses,3 and preliminary observations suggest that it may be safer than other antidepressants when given to patients with epilepsy.2467 Nevertheless, the risk of precipitating phenytoin and carbamazepine89 intoxication should always be considered and careful monitoring of plasma anticonvulsant drug levels is mandatory whenever viloxazine is prescribed in these patients.
